Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Equity Income: 2020-2024

Historic Equity Income for Beam Therapeutics (BEAM) over the last 5 years, with Dec 2024 value amounting to -$14.1 million.

  • Beam Therapeutics' Equity Income rose 339.20% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 145.03%. This contributed to the annual value of -$14.1 million for FY2024, which is 24.20% up from last year.
  • Latest data reveals that Beam Therapeutics reported Equity Income of -$14.1 million as of FY2024, which was up 24.20% from -$18.6 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Equity Income registered a high of $17.7 million during FY2021, and its lowest value of -$25.5 million during FY2022.
  • In the last 3 years, Beam Therapeutics' Equity Income had a median value of -$18.6 million in 2023 and averaged -$19.4 million.
  • Its Equity Income has fluctuated over the past 5 years, first soared by 3,321.66% in 2021, then tumbled by 244.15% in 2022.
  • Beam Therapeutics' Equity Income (Yearly) stood at $517,000 in 2020, then skyrocketed by 3,321.66% to $17.7 million in 2021, then crashed by 244.15% to -$25.5 million in 2022, then grew by 27.09% to -$18.6 million in 2023, then climbed by 24.20% to -$14.1 million in 2024.